{"id":"switching-bupropion-sr","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Dry mouth"},{"rate":"10-20%","effect":"Insomnia"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This action is thought to contribute to its antidepressant and smoking cessation effects. Bupropion-SR also has some effect on serotonin levels, but this is less pronounced than its effect on norepinephrine and dopamine.","oneSentence":"Bupropion-SR is a norepinephrine-dopamine reuptake inhibitor, which increases the levels of these neurotransmitters in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:04.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Smoking cessation"}]},"trialDetails":[{"nctId":"NCT01421342","phase":"PHASE3","title":"VA Augmentation and Switching Treatments for Improving Depression Outcomes","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2012-12","conditions":"Major Depressive Disorder","enrollment":1522}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Switching: Bupropion-SR","genericName":"Switching: Bupropion-SR","companyName":"VA Office of Research and Development","companyId":"va-office-of-research-and-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bupropion-SR is used to treat Major Depressive Disorder, and it works by inhibiting the sodium-dependent dopamine transporter. This action is due to its classification as a small molecule inhibitor of the dopamine transporter.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}